Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing ...Middle East

Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC Aadi Enters Agreement to Sell FYARRO® and Associated Infrastructure to KAKEN Pharmaceutical for $100M; Announces PIPE Financing of $100M Cumulative...

Read More Details
Finally We wish PressBee provided you with enough information of ( Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing )

Also on site :

• 'Hissing door mid-air': AI flight to Hong Kong spooks flyers; crew use napkins to 'fix' issue
• Putin says there& 039;s no evidence Iran wants nuclear weapons
• Israel says it killed a commander of Iranian force that oversees proxy militias.